EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis

Moayed Ibrahim iD, Catherine Murphree, Kirtesh Patel, Matthew Mastrodomenico, Nakhle S Saba, Hana Safah, Janet Schmid, Francisco Socola iD

Cancer Reports · 2024

DOI: 10.1002/cnr2.2054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Moayed Ibrahim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: B7-H1 Antigen, Janus Kinase 2, Primary Myelofibrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carol Lavin Bernick Faculty Grant Program at Tulane University School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It has been described in mice models that myeloproliferative neoplasm (MPN) with JAK2‐V617F mutation has an increased expression of programmed death‐ligand 1 (PD‐L1) in megakaryocytes leading to cancer immune evasion by inhibiting the T‐lymphocytes.

Aims

To quantify and compare the PD‐L1 expression on bone marrow (BM) of patients with MPN JAK2 positive, negative, and normal controls.

Methods

We collected BM of patients with MPN JAK2 positive, negative and normal controls from 1990 to 2019. We also created a scoring system to quantify PD‐L1 expression in megakaryocytes.

Results

We obtained 14 BM with JAK2 positive PMF, 5 JAK2 negative PMF, and 10 patients with normal BM biopsies. PD‐L1 expression was higher in the JAK2 positive group compared with the control group with a score of 212.6 versus 121.1 ( t ‐value 2.05, p ‐value 0.025). In addition, the score was higher in the PMF group regardless of JAK2 mutational status when compared with the control group with score of 205.9 versus 121.1 ( t ‐value 2.12, p ‐value 0.021). There was no difference in the PD‐L1 score between the JAK2 negative versus the control group 187.2 versus 121.1 ( t ‐value 1.02, p ‐value 0.162).

Conclusion

These findings suggest that PMF patients with a JAK2 mutation have a higher PD‐L1 expression in megakaryocytes compared with the control group. We postulate that the combination of checkpoint and JAK2 inhibitors may be an active treatment option in JAK2 mutated PMF given the higher PD‐L1 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenJanus Kinase 2Primary MyelofibrosisHumansMaleFemaleMiddle AgedAgedAdultMutationBone MarrowMegakaryocytesAged, 80 and overCase-Control Studies

Stichwörter der Autor:innen

JAK/STAT pathwayPD‐L1immunotherapyprimary myelofibrosissecondary myelofibrosis

Substanzen

B7-H1 AntigenCD274 protein, humanJanus Kinase 2JAK2 protein, human

Autor:innen und Institutionen

  • Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA.
  • Delta Pathology Group, Shreveport, Louisiana, USA.
  • Pathology Department, Tulane University, New Orleans, Louisiana, USA.
  • Hematology and Bone Marrow Transplant, University of California Davis, Sacramento, California, USA.

ORCID-Profile: Moayed Ibrahim, Francisco Socola

Förderung

  • Carol Lavin Bernick Faculty Grant Program at Tulane University School of Medicine

Zitieren

APA

Ibrahim, M., Murphree, C., Patel, K., Mastrodomenico, M., Saba, N. S., Safah, H., Schmid, J., & Socola, F. (2024). Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis. Cancer Reports. https://doi.org/10.1002/cnr2.2054

Vancouver

Ibrahim M, Murphree C, Patel K, Mastrodomenico M, Saba NS, Safah H, et al. Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis. Cancer Reports. 2024. doi:10.1002/cnr2.2054

BibTeX
@article{Ibrahim2024,
  author = {Ibrahim, Moayed and Murphree, Catherine and Patel, Kirtesh and Mastrodomenico, Matthew and Saba, Nakhle S and Safah, Hana and Schmid, Janet and Socola, Francisco},
  title = {Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.2054}
}
Kostenlos starten →